In reply. QTc prolongation and delamanid: access and safety

Affiliations

¹ Tuberculosis Research Unit, Case Western Reserve University, Cleveland, Ohio, USA. jenniferfurin@gmail.com.
² Tuberculosis Research Unit, Case Western Reserve University, Cleveland, Ohio, USA.
³ Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
⁴ Division of Medical Microbiology and Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

Comment

Jennifer Furin et al. Int J Tuberc Lung Dis. 2015 Oct.

. 2015 Oct;19(10):1262-3.

doi: 10.5588/ijtld.15.0541-2.

¹ Tuberculosis Research Unit, Case Western Reserve University, Cleveland, Ohio, USA. jenniferfurin@gmail.com.
² Tuberculosis Research Unit, Case Western Reserve University, Cleveland, Ohio, USA.
³ Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
⁴ Division of Medical Microbiology and Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.

No abstract available

Comment on

QTc prolongation and treatment of multidrug-resistant tuberculosis.
Harausz E, Cox H, Rich M, Mitnick CD, Zimetbaum P, Furin J. Harausz E, et al. Int J Tuberc Lung Dis. 2015 Apr;19(4):385-91. doi: 10.5588/ijtld.14.0335. Int J Tuberc Lung Dis. 2015. PMID: 25859992 Review.
Delamanid and QT prolongation in the treatment of multidrug-resistant tuberculosis.
Gupta R, Geiter LJ, Hafkin J, Wells CD. Gupta R, et al. Int J Tuberc Lung Dis. 2015 Oct;19(10):1261-2. doi: 10.5588/ijtld.15.0541. Int J Tuberc Lung Dis. 2015. PMID: 26459547 No abstract available.